Integris Medtech recalibrates proposed IPO, reducing fresh issue component

SENSEX 73,249.39

 -460.30

NIFTY 22,687.65

 -123.70

CRUDEOIL 9,492.00

+ 284.00

GOLD 144,585.00

 -1,494.00

SILVER 203,000.00

 -6,168.00

SENSEX 73,249.39

 -460.30

NIFTY 22,687.65

 -123.70

NIFTY 22,687.65

 -123.70

CRUDEOIL 9,492.00

+ 284.00

CRUDEOIL 9,492.00

+ 284.00

GOLD 144,585.00

 -1,494.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

The revision reflects market volatility amid geopolitical developments, with the company prioritising debt reduction

By BL Mumbai Bureau

Updated - October 22, 2026 at 06:59 PM. | Mumbai

About 85 per cent of the revised IPO structure, ie approximately ₹509.85 crore, will go towards repayment or prepayment of borrowings across its wholly owned and step-down subsidiaries, including Translumina Therapeutics, Transhealth, CPC Diagnostics, Chemopharm and Research Instruments

Integris Medtech Ltd has recalibrated its proposed initial public offering (IPO), reducing the fresh issue component from ₹925 crore to ₹600 crore – reflecting a focus on debt reduction, according to an addendum to its Draft Red Herring Prospectus (DRHP).

The revision reflects a calibrated approach to capital raising amid evolving market dynamics and heightened volatility arising from geopolitical developments, with the company retaining a significant focus on debt reduction, it added.

About 85 per cent of the revised IPO structure, ie approximately ₹509.85 crore, will go towards repayment or prepayment of borrowings across its wholly owned and step-down subsidiaries, including Translumina Therapeutics, Transhealth, CPC Diagnostics, Chemopharm and Research Instruments. The proposed debt reduction could strengthen the company’s consolidated balance sheet, lower future finance costs and provide greater financial flexibility for its medical technology operations, according to the document.

OFS reduction

The revised offer structure involves promoters Gurmit Singh Chugh and Punita Sharma withdrawing their proposed offer for sale (OFS) participation, allowing them to retain their existing shareholdings through the proposed transaction, it said. Meanwhile, promoter Evercure Holdings Pte. Ltd has reduced its proposed OFS to up to 1,08,37,266 equity shares, it added. The restructuring indicates a measured approach to shareholder dilution and capital mobilisation, while prioritising the company’s existing debt obligations, the document said.

Integris Medtech Ltd’s portfolio includes medical products and laboratory solutions, and it is present in two major segments - cardiovascular devices (including drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions) and laboratory solutions, which serve clinical, research, and industrial laboratories. Co-founded by Gurmit Singh Chugh and Punita Sharma, Integris’s journey began with the sales of cardiology products and it has transitioned into advanced manufacturing with introduction of technologies such as Yukon drug eluting stent.

Published on October 22, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers